Merck

MRK

Market cap $294B

Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck press release announcing European Commission approval of ENFLONSIA.

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Merck (MRK) is rated Very Attractive due to strong economic earnings, 20% ROIC, and undervaluation at $120/share. GAAP and Street Earnings understate MRK's profitability; Core Earnings provide a superior measure, revealing significant hidden and reported unusual expenses. MRK's 1Q26 Street EPS estimate is understated by $3.29/share, suggesting a strong likelihood of beating consensus expectations.

MRK's Keytruda, driving over half of its pharma sales, remains in focus as Q1 nears, with growth expected from new indications and strong uptake.

The FDA grants priority review to Merck and Daiichi's BLA for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer.

In the latest trading session, Merck (MRK) closed at $120.15, marking a -1.05% move from the previous day.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--I-DXd BLA Acceptance.

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and Merck's, known as MSD outside of the United States and Canada, (NYSE: MRK) Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Ifinatamab deruxtecan is a specifica.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Terns will receive $53.00 in cash for each share of Terns that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.